Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC.
10.3779/j.issn.1009-3419.2025.102.29
- Author:
Yuling ZHONG
1
;
Jingyi WANG
1
;
Lin WU
1
Author Information
1. The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School
of Medicine, Central South University, Changsha 410013, China.
- Publication Type:English Abstract
- Keywords:
Antibody-drug conjugates;
Biomarker;
Lung neoplasms;
Toxic reactions
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/immunology*;
Immunoconjugates/therapeutic use*;
Lung Neoplasms/immunology*;
Antineoplastic Agents/therapeutic use*;
Immunotherapy
- From:
Chinese Journal of Lung Cancer
2025;28(8):621-628
- CountryChina
- Language:Chinese
-
Abstract:
Advances in targeted therapy and immunotherapy have significantly improved clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC), reshaping treatment paradigms. However, most patients ultimately face drug resistance, with limited options for subsequent therapies and suboptimal treatment efficacy, presenting a prominent challenge in current clinical practice. Antibody-drug conjugates (ADCs), characterized by high efficacy and favorable safety profiles, have emerged as a promising therapeutic frontier in recent years. This systematic review provides a comprehensive overview of the latest advancements in ADCs-based therapies for lung cancer, alongside discussions of the prevailing challenges in this rapidly evolving domain.
.
